Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Takeda Pharmaceutical Net Change in Property, Plant, and Equipment 2010-2024 | TAK

Takeda Pharmaceutical annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2024. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
  • Takeda Pharmaceutical net change in property, plant, and equipment for the quarter ending December 31, 2024 was $-0.368B, a 9.59% increase year-over-year.
  • Takeda Pharmaceutical net change in property, plant, and equipment for the twelve months ending December 31, 2024 was $-2.871B, a 9.29% increase year-over-year.
  • Takeda Pharmaceutical annual net change in property, plant, and equipment for 2024 was $-1.151B, a 11.34% increase from 2023.
  • Takeda Pharmaceutical annual net change in property, plant, and equipment for 2023 was $-1.034B, a 4.35% decline from 2022.
  • Takeda Pharmaceutical annual net change in property, plant, and equipment for 2022 was $-1.081B, a 77.56% increase from 2021.
  
Takeda Pharmaceutical Annual Net Change in Property, Plant, and Equipment
(Millions of US $)
2024 $-1,151
2023 $-1,034
2022 $-1,081
2021 $-609
2020 $-1,053
2019 $-243
2018 $-576
2017 $-546
2016 $-400
2015 $-130
2014 $-367
2013 $-849
2012 $-519
2011 $-1,488
2010 $-927
2009 $-397
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $47.092B $30.087B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.912B 32.23
Zoetis (ZTS) United States $74.412B 27.76
Daiichi Sankyo, - (DSNKY) Japan $51.611B 26.26
Sandoz Group AG (SDZNY) Switzerland $21.516B 0.00
Summit Therapeutics (SMMT) United States $19.465B 0.00
Merck (MKKGY) Germany $16.963B 12.43
United Therapeutics (UTHR) United States $14.451B 12.78
Shionogi (SGIOY) Japan $13.900B 13.93
Neurocrine Biosciences (NBIX) United States $12.238B 41.92
IPSEN (IPSEY) France $9.702B 0.00
Orion OYJ (ORINY) Finland $9.462B 25.59
Corcept Therapeutics (CORT) United States $8.233B 66.93
Stevanato Group S.p.A (STVN) Italy $6.929B 42.37
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $5.993B 0.00
Grifols, S.A (GRFS) Spain $5.748B 0.00
Ionis Pharmaceuticals (IONS) United States $5.325B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.811B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.998B 10.50
Crinetics Pharmaceuticals (CRNX) United States $2.858B 0.00
Hypermarcas (HYPMY) Brazil $2.716B 17.87
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.288B 12.37
BioCryst Pharmaceuticals (BCRX) United States $2.277B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.979B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.809B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.746B 0.00
Indivior (INDV) United States $1.711B 7.26
ARS Pharmaceuticals (SPRY) United States $1.521B 0.00
Dyne Therapeutics (DYN) United States $1.391B 0.00
Guardian Pharmacy Services (GRDN) United States $1.354B 0.00
Evotec AG (EVO) Germany $1.342B 0.00
Ocular Therapeutix (OCUL) United States $1.297B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.079B 21.59
Harrow (HROW) United States $0.998B 0.00
Ardelyx (ARDX) United States $0.964B 0.00
Collegium Pharmaceutical (COLL) United States $0.938B 5.06
Avadel Pharmaceuticals (AVDL) Ireland $0.892B 0.00
Enliven Therapeutics (ELVN) United States $0.870B 0.00
Akebia Therapeutics (AKBA) United States $0.791B 0.00
Cronos Group (CRON) Canada $0.790B 0.00
Xeris Biopharma Holdings (XERS) United States $0.788B 0.00
AleAnna (ANNA) United States $0.603B 0.00
KalVista Pharmaceuticals (KALV) United States $0.591B 0.00
Elite Pharmaceuticals (ELTP) United States $0.576B 0.00
USANA Health Sciences (USNA) United States $0.562B 12.22
Xencor (XNCR) United States $0.551B 0.00
Regulus Therapeutics (RGLS) United States $0.550B 0.00
Bioventus (BVS) United States $0.539B 13.67
Relay Therapeutics (RLAY) United States $0.528B 0.00
Zevra Therapeutics (ZVRA) United States $0.471B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.465B 0.00
Altimmune (ALT) United States $0.455B 0.00
Oruka Therapeutics (ORKA) United States $0.444B 0.00
Siga Technologies (SIGA) United States $0.440B 9.19
Amylyx Pharmaceuticals (AMLX) United States $0.437B 0.00
CytoDyn (CYDY) United States $0.435B 0.00
Tourmaline Bio (TRML) United States $0.424B 0.00
Verve Therapeutics (VERV) United States $0.410B 0.00
Savara (SVRA) United States $0.387B 0.00
Organogenesis (ORGO) United States $0.362B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.349B 9.43
Tonix Pharmaceuticals Holding (TNXP) United States $0.308B 0.00
Heron Therapeutics (HRTX) United States $0.291B 0.00
Nature's Sunshine Products (NATR) United States $0.281B 25.92
Aquestive Therapeutics (AQST) United States $0.277B 0.00
MediWound (MDWD) Israel $0.231B 0.00
ProKidney (PROK) United States $0.211B 0.00
Nanobiotix S.A (NBTX) France $0.195B 0.00
Journey Medical (DERM) United States $0.188B 0.00
Esperion Therapeutics (ESPR) United States $0.173B 0.00
4D Molecular Therapeutics (FDMT) United States $0.172B 0.00
Wellgistics Health (WGRX) United States $0.167B 0.00
Profound Medical (PROF) Canada $0.160B 0.00
Aclaris Therapeutics (ACRS) United States $0.158B 0.00
Inhibikase Therapeutics (IKT) United States $0.155B 0.00
OmniAb (OABI) United States $0.153B 0.00
Avita Medical (RCEL) United States $0.153B 0.00
Larimar Therapeutics (LRMR) United States $0.147B 0.00
Nektar Therapeutics (NKTR) United States $0.138B 0.00
Aldeyra Therapeutics (ALDX) United States $0.137B 0.00
Liminatus Pharma (LIMN) $0.136B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.132B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Protara Therapeutics (TARA) United States $0.121B 0.00
Lyell Immunopharma (LYEL) United States $0.119B 0.00
Achieve Life Sciences (ACHV) Canada $0.116B 0.00
Korro Bio (KRRO) United States $0.110B 0.00
VAXART, INC (VXRT) United States $0.107B 0.00
Cardiol Therapeutics (CRDL) Canada $0.103B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.102B 0.00
Cassava Sciences (SAVA) United States $0.099B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Inotiv (NOTV) United States $0.096B 0.00
Lexeo Therapeutics (LXEO) United States $0.095B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.093B 0.00
Fractyl Health (GUTS) United States $0.093B 0.00
Arch Biopartners (ACHFF) Canada $0.087B 0.00
Champions Oncology (CSBR) United States $0.085B 14.05
Galectin Therapeutics (GALT) United States $0.078B 0.00
Pyxis Oncology (PYXS) United States $0.077B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.075B 55.89
ESSA Pharma (EPIX) Canada $0.074B 0.00
Surrozen (SRZN) United States $0.073B 0.00
Nutriband (NTRB) United States $0.072B 0.00
Vivani Medical (VANI) United States $0.071B 0.00
Unicycive Therapeutics (UNCY) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.067B 0.00
Metagenomi (MGX) United States $0.067B 0.00
Assertio Holdings (ASRT) United States $0.065B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Context Therapeutics (CNTX) United States $0.055B 0.00
Gain Therapeutics (GANX) United States $0.054B 0.00
Prelude Therapeutics (PRLD) United States $0.051B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
NRx Pharmaceuticals (NRXP) United States $0.047B 0.00
Mural Oncology (MURA) Ireland $0.046B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.042B 0.00
Avalo Therapeutics (AVTX) United States $0.040B 0.00
Iterum Therapeutics (ITRM) Ireland $0.039B 0.00
Karyopharm Therapeutics (KPTI) United States $0.039B 0.00
ElectroCore (ECOR) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.035B 0.00
Rafael Holdings (RFL) United States $0.035B 0.00
Acrivon Therapeutics (ACRV) United States $0.034B 0.00
FibroGen (FGEN) United States $0.032B 0.00
PolyPid (PYPD) Israel $0.028B 0.00
Jupiter Neurosciences (JUNS) United States $0.028B 0.00
Relmada Therapeutics (RLMD) United States $0.024B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
China SXT Pharmaceuticals (SXTC) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
BioVie (BIVI) United States $0.020B 0.00
Mannatech (MTEX) United States $0.018B 0.00
Lipocine (LPCN) United States $0.018B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
DURECT (DRRX) United States $0.017B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
VYNE Therapeutics (VYNE) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.015B 0.00
MEI Pharma (MEIP) United States $0.015B 0.00
SHINECO (SISI) China $0.015B 0.00
Ainos (AIMD) United States $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.014B 0.00
GlycoMimetics (GLYC) United States $0.014B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Mangoceuticals (MGRX) United States $0.013B 0.00
Scienture Holdings (SCNX) United States $0.012B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.83
Talphera (TLPH) United States $0.010B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Aditxt (ADTX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00